文献速递核素与放射性配体治疗

锕-225与镥-177标记的PSMA-I&T的体外剂量效应关系

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-05-12

在PSMA表达的PC3-PIP前列腺癌细胞系中,比较[225Ac]Ac-PSMA-I&T与[177Lu]Lu-PSMA-I&T的体外结合特性、DNA双链断裂修复动力学及克隆存活,发现两者结合特性相似,但[225Ac]Ac-PSMA-I&T的DNA双链断裂修复更慢,相对生物学效应(RBE)为[177Lu]Lu-PSMA-I&T的4.2倍。

要点

  • 在PC3-PIP细胞中,[225Ac]Ac-PSMA-I&T与[177Lu]Lu-PSMA-I&T的结合特性相似。
  • [225Ac]Ac-PSMA-I&T处理的细胞DNA双链断裂修复动力学较[177Lu]Lu-PSMA-I&T慢。
  • [225Ac]Ac-PSMA-I&T的RBE为[177Lu]Lu-PSMA-I&T的4.2倍。

核心结论

  • 用镥-177或锕-225标记PSMA-I&T后体外结合特性相似,提示本研究中不同的生物学效应并非由两种示踪剂摄取差异引起。
  • [225Ac]Ac-PSMA-I&T较[177Lu]Lu-PSMA-I&T更慢的修复动力学与锕-225照射产生更复杂、更难修复的DNA双链断裂的假设相符。
  • [225Ac]Ac-PSMA-I&T较[177Lu]Lu-PSMA-I&T更高的RBE突显了其治疗前列腺癌的治疗潜力。

研究设计与样本

  • 体外研究,使用PSMA表达的前列腺癌细胞系PC3-PIP进行结合与置换实验、53BP1焦点计数、克隆存活实验及剂量学评估。

主要发现

  • [225Ac]Ac-PSMA-I&T与[177Lu]Lu-PSMA-I&T的结合特性相似。
  • [225Ac]Ac-PSMA-I&T处理的细胞53BP1焦点(DNA双链断裂标志)修复动力学较[177Lu]Lu-PSMA-I&T处理的细胞慢。
  • [225Ac]Ac-PSMA-I&T与[177Lu]Lu-PSMA-I&T特异性靶向均导致克隆存活呈剂量依赖性下降。
  • 剂量学评估后,[225Ac]Ac-PSMA-I&T的RBE为[177Lu]Lu-PSMA-I&T的4.2倍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Targeting the prostate-specific membrane antigen (PSMA) using lutetium-177-labeled PSMA-specific tracers has become a very promising novel therapy option for prostate cancer (PCa). The efficacy of this therapy might be further improved by replacing the β-emitting lutetium-177 with the α-emitting actinium-225. Actinium-225 is thought to have a higher therapeutic efficacy due to the high linear energy transfer (LET) of the emitted α-particles, which can increase the amount and complexity of the therapy induced DNA double strand breaks (DSBs). Here we evaluated the relative biological effectiveness of [225Ac]Ac-PSMA-I&T and [177Lu]Lu-PSMA-I&T by assessing in vitro binding characteristics, dosimetry, and therapeutic efficacy. METHODS AND RESULTS: The PSMA-expressing PCa cell line PC3-PIP was used for all in vitro assays. First, binding and displacement assays were performed, which revealed similar binding characteristics between [225Ac]Ac-PSMA-I&T and [177Lu]Lu-PSMA-I&T. Next, the assessment of the number of 53BP1 foci, a marker for the number of DNA double strand breaks (DSBs), showed that cells treated with [225Ac]Ac-PSMA-I&T had slower DSB repair kinetics compared to cells treated with [177Lu]Lu-PSMA-I&T. Additionally, clonogenic survival assays showed that specific targeting with [225Ac]Ac-PSMA-I&T and [177Lu]Lu-PSMA-I&T caused a dose-dependent decrease in survival. Lastly, after dosimetric assessment, the relative biological effectiveness (RBE) of [225Ac]Ac-PSMA-I&T was found to be 4.2 times higher compared to [177Lu]Lu-PSMA-I&T. CONCLUSION: We found that labeling of PSMA-I&T with lutetium-177 or actinium-225 resulted in similar in vitro binding characteristics, indicating that the distinct biological effects observed in this study are not caused by a difference in uptake of the two tracers. The slower repair kinetics of [225Ac]Ac-PSMA-I&T compared to [177Lu]Lu-PSMA-I&T correlates to the assumption that irradiation with actinium-225 causes more complex, more difficult to repair DSBs compared to lutetium-177 irradiation. Furthermore, the higher RBE of [225Ac]Ac-PSMA-I&T compared to [177Lu]Lu-PSMA-I&T underlines the therapeutic potential for the treatment of PCa.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ruigrok EAM, Tamborino G, de Blois E, et al. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T. Eur J Nucl Med Mol Imaging. 2022. PMID: 35556158. doi:10.1007/s00259-022-05821-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。